The following recommendations support optimal outcomes: Prescribing decisions should be individualised, weighing the substantial benefits of improved glycaemic control and weight reduction against any theoretical skeletal concerns
When accounting for full treatment adherence, that number climbed to 15.7%
Schedule prompt medical evaluation (within 24-48 hours) for: Gradually worsening shortness of breath over days to weeks Dyspnea with exertion that is new or significantly worse than baseline Breathing difficulty accompanied by persistent cough or fever Leg swelling, weight gain, or orthopnea (difficulty breathing when lying flat) Respiratory symptoms associated with severe ongoing nausea, vomiting, or inability to maintain hydration Patients should not discontinue GLP-1 medications without medical guidance (except in cases of suspected severe allergic reactions), but should contact their healthcare provider promptly to discuss respiratory symptoms

Customized care paths designed for trust, privacy, or speed Once a patient is matched to a persona, our platform routes them into a care path that fits how they actually want to engage: Privacy-Focused Patients (Silent Sufferers): discreet communication options and minimal-touch workflows that reduce being perceived while still keeping care compliant and safe
This paper reviews the structural and functional characteristics of GLP-1R
Doctors may prescribe oral medications or intrauterine devices that release progesterone directly into the uterus